These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29090394)

  • 1. Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
    Abaasa A; Hendrix C; Gandhi M; Anderson P; Kamali A; Kibengo F; Sanders EJ; Mutua G; Bumpus NN; Priddy F; Haberer JE
    AIDS Behav; 2018 Apr; 22(4):1165-1173. PubMed ID: 29090394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
    Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
    Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
    Koss CA; Liu AY; Castillo-Mancilla J; Bacchetti P; McHugh C; Kuncze K; Morrow M; Louie A; Seifert S; Okochi H; MaWhinney S; Gandhi M; Anderson PL
    AIDS; 2018 Sep; 32(15):2189-2194. PubMed ID: 30212404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
    Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
    AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
    Velloza J; Bacchetti P; Hendrix CW; Murnane P; Hughes JP; Li M; Curlin ME; Holtz TH; Mannheimer S; Marzinke MA; Amico KR; Liu A; Piwowar-Manning E; Eshleman SH; Dye BJ; Gandhi M; Grant RM;
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):149-158. PubMed ID: 31335588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
    Koss CA; Charlebois ED; Ayieko J; Kwarisiima D; Kabami J; Balzer LB; Atukunda M; Mwangwa F; Peng J; Mwinike Y; Owaraganise A; Chamie G; Jain V; Sang N; Olilo W; Brown LB; Marquez C; Zhang K; Ruel TD; Camlin CS; Rooney JF; Black D; Clark TD; Gandhi M; Cohen CR; Bukusi EA; Petersen ML; Kamya MR; Havlir DV;
    Lancet HIV; 2020 Apr; 7(4):e249-e261. PubMed ID: 32087152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
    AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
    Kebaabetswe PM; Stirratt MJ; McLellan-Lemal E; Henderson FL; Gray SC; Rose CE; Williams T; Paxton LA
    AIDS Behav; 2015 May; 19(5):758-69. PubMed ID: 25186785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin.
    Mboup A; Béhanzin L; Guédou F; Giguère K; Geraldo N; Zannou DM; Kêkê RK; Bachabi M; Gangbo F; Affolabi D; Marzinke MA; Hendrix C; Diabaté S; Alary M
    Medicine (Baltimore); 2020 May; 99(21):e20063. PubMed ID: 32481273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.
    Musinguzi N; Muganzi CD; Boum Y; Ronald A; Marzinke MA; Hendrix CW; Celum C; Baeten JM; Bangsberg DR; Haberer JE;
    AIDS; 2016 Apr; 30(7):1121-9. PubMed ID: 26785125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
    van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
    Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
    AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.